BR112018068414A2 - derivados de ácido a-truxílico e composições farmacêuticas dos mesmos - Google Patents
derivados de ácido a-truxílico e composições farmacêuticas dos mesmosInfo
- Publication number
- BR112018068414A2 BR112018068414A2 BR112018068414A BR112018068414A BR112018068414A2 BR 112018068414 A2 BR112018068414 A2 BR 112018068414A2 BR 112018068414 A BR112018068414 A BR 112018068414A BR 112018068414 A BR112018068414 A BR 112018068414A BR 112018068414 A2 BR112018068414 A2 BR 112018068414A2
- Authority
- BR
- Brazil
- Prior art keywords
- truxylic
- pharmaceutical compositions
- acid derivatives
- compound
- fabp
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07C69/753—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring of polycyclic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
- C07C205/55—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
- C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/25—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C61/04—Saturated compounds having a carboxyl group bound to a three or four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07C69/757—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
- C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D309/06—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
- C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
- C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
- C07C2603/18—Fluorenes; Hydrogenated fluorenes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Addiction (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Quinoline Compounds (AREA)
- Pyrane Compounds (AREA)
Abstract
a presente invenção proporciona um composto e método de inibição da atividade de uma proteína de ligação a ácido graxo (fabp) compreendendo o contato da fabp com um composto, tendo o referido composto a estrutura:
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662307262P | 2016-03-11 | 2016-03-11 | |
US62/307,262 | 2016-03-11 | ||
PCT/US2017/021711 WO2017156354A1 (en) | 2016-03-11 | 2017-03-10 | α-TRUXILLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112018068414A2 true BR112018068414A2 (pt) | 2019-01-22 |
BR112018068414B1 BR112018068414B1 (pt) | 2022-08-23 |
Family
ID=59789897
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018068414-7A BR112018068414B1 (pt) | 2016-03-11 | 2017-03-10 | Derivados de ácido a-truxílico e composições farmacêuticas dos mesmos |
Country Status (12)
Country | Link |
---|---|
US (3) | US10968163B2 (pt) |
EP (1) | EP3452441A4 (pt) |
JP (1) | JP6976581B2 (pt) |
KR (1) | KR102365059B1 (pt) |
CN (1) | CN109415295B (pt) |
AU (1) | AU2017230790B2 (pt) |
BR (1) | BR112018068414B1 (pt) |
CA (1) | CA3017496A1 (pt) |
EA (1) | EA201892045A1 (pt) |
MX (1) | MX2018010801A (pt) |
SG (2) | SG10202008700VA (pt) |
WO (1) | WO2017156354A1 (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2874987B1 (en) | 2012-07-20 | 2020-03-25 | The Research Foundation Of State University Of New York | alpha-AND gamma-TRUXILLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF |
US10968163B2 (en) | 2016-03-11 | 2021-04-06 | The Research Foundation For The State University Of New York | Alpha-truxillic acid derivatives and pharmaceutical compositions thereof |
US20230017948A1 (en) * | 2019-11-25 | 2023-01-19 | The Research Foundation For The State University Of New York | Combination therapy using fabp5 inhibitors with taxanes for treatment of cancer |
KR20230076860A (ko) * | 2020-10-08 | 2023-05-31 | 더 리서치 파운데이션 포 더 스테이트 유니버시티 오브 뉴욕 | 선택적 fabp5 억제제로서의 트룩실산 모노에스테르-유도체 및 이의 약제학적 조성물 및 용도 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3903297A (en) | 1973-11-01 | 1975-09-02 | Upjohn Co | Method of treatment and prophylaxis of gastric hypersecretion and gastric and duodenal ulcers using prostaglandin analogs |
JP2001199884A (ja) | 2000-01-21 | 2001-07-24 | Seiwa Yakuhin Kk | 鎮痛作用剤 |
ES2189602B1 (es) * | 2000-10-11 | 2004-08-01 | Universidad De Murcia | Procedimiento para la inmovilizacion de un ligando sobre un soporte. |
JP2002154959A (ja) * | 2000-11-15 | 2002-05-28 | Seiwa Yakuhin Kk | 鎮痛抗炎症作用剤 |
EP1443919A4 (en) | 2001-11-16 | 2006-03-22 | Bristol Myers Squibb Co | DOUBLE INHIBITORS OF THE FATTY ACID BINDING PROTEIN OF THE ADIPOCYTES AND THE FATTY ACID BINDING PROTEIN OF KERATINOCYTES |
JP2011507910A (ja) * | 2007-12-21 | 2011-03-10 | ユニバーシティー オブ ロチェスター | 真核生物の寿命を変更するための方法 |
WO2010083532A1 (en) | 2009-01-19 | 2010-07-22 | The Research Foundaton Of State University Of New York | Fatty acid binding proteins as drug targets for modulation of endocannabinoids |
CN101838239B (zh) | 2010-02-02 | 2012-03-21 | 中国科学院广州生物医药与健康研究院 | 一种吡唑类化合物及其组合物和应用 |
EP2874987B1 (en) * | 2012-07-20 | 2020-03-25 | The Research Foundation Of State University Of New York | alpha-AND gamma-TRUXILLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF |
MX2015002624A (es) * | 2012-09-12 | 2015-06-23 | Hoffmann La Roche | Nuevas tiofenilamidas no anuladas como inhibidores de las proteinas de union a acido graso (fabp) 4 y/o 5. |
US10968163B2 (en) | 2016-03-11 | 2021-04-06 | The Research Foundation For The State University Of New York | Alpha-truxillic acid derivatives and pharmaceutical compositions thereof |
-
2017
- 2017-03-10 US US16/080,493 patent/US10968163B2/en active Active
- 2017-03-10 EA EA201892045A patent/EA201892045A1/ru unknown
- 2017-03-10 SG SG10202008700VA patent/SG10202008700VA/en unknown
- 2017-03-10 CA CA3017496A patent/CA3017496A1/en active Pending
- 2017-03-10 KR KR1020187028746A patent/KR102365059B1/ko active IP Right Grant
- 2017-03-10 MX MX2018010801A patent/MX2018010801A/es unknown
- 2017-03-10 BR BR112018068414-7A patent/BR112018068414B1/pt active IP Right Grant
- 2017-03-10 WO PCT/US2017/021711 patent/WO2017156354A1/en active Application Filing
- 2017-03-10 AU AU2017230790A patent/AU2017230790B2/en active Active
- 2017-03-10 EP EP17764162.8A patent/EP3452441A4/en active Pending
- 2017-03-10 SG SG11201807365QA patent/SG11201807365QA/en unknown
- 2017-03-10 CN CN201780016751.4A patent/CN109415295B/zh active Active
- 2017-03-10 JP JP2018567019A patent/JP6976581B2/ja active Active
-
2021
- 2021-02-11 US US17/174,030 patent/US11739047B2/en active Active
-
2023
- 2023-07-03 US US18/346,363 patent/US20240092725A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN109415295A (zh) | 2019-03-01 |
CA3017496A1 (en) | 2017-09-14 |
JP6976581B2 (ja) | 2021-12-08 |
BR112018068414B1 (pt) | 2022-08-23 |
EP3452441A4 (en) | 2019-10-23 |
US11739047B2 (en) | 2023-08-29 |
KR20180120230A (ko) | 2018-11-05 |
CN109415295B (zh) | 2022-05-17 |
WO2017156354A1 (en) | 2017-09-14 |
AU2017230790B2 (en) | 2021-07-08 |
US20240092725A1 (en) | 2024-03-21 |
US10968163B2 (en) | 2021-04-06 |
SG11201807365QA (en) | 2018-09-27 |
EA201892045A1 (ru) | 2019-04-30 |
KR102365059B1 (ko) | 2022-02-18 |
MX2018010801A (es) | 2019-02-07 |
AU2017230790A1 (en) | 2018-11-01 |
SG10202008700VA (en) | 2020-10-29 |
US20210179535A1 (en) | 2021-06-17 |
EP3452441A1 (en) | 2019-03-13 |
US20190062261A1 (en) | 2019-02-28 |
JP2019510086A (ja) | 2019-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2021005987A2 (es) | Compuestos de anillo fusionado | |
BR112019002275A2 (pt) | inibidores aminopirimidina de ssaos | |
MX2019009861A (es) | Composiciones farmaceuticas de un derivado de acido biliar y microbioma y usos de las mismas. | |
BR112018005497A2 (pt) | compostos heterocíclicos e usos dos mesmos | |
CL2017001204A1 (es) | Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa | |
BR112017025499A2 (pt) | benefícios da suplementação com n-acetil cisteína e glicina para melhorar os níveis de glutationa | |
BR112015031073A2 (pt) | inibidores bicíclicos de bromodomínio | |
BR112019001607A2 (pt) | inibidores macrocíclicos de quinases | |
DK3330259T3 (da) | 1,3,4-oxadiazolamidderivativ-forbindelse som histondeacetylase-6-inhibitor og farmaceutisk sammensætning indeholdende denne | |
BR112018068414A2 (pt) | derivados de ácido a-truxílico e composições farmacêuticas dos mesmos | |
EA201691134A1 (ru) | Новые ингибиторы глутаминазы | |
BR112017009405A2 (pt) | composições antibióticas. | |
BR112018010389A8 (pt) | método para preparação de compostos | |
BR112016024494A2 (pt) | análogos de peptídeo com sonda(s) de aminoácidos ramificados | |
BR112014009415A2 (pt) | inibidores de arginase e suas aplicações terapêuticas | |
BR112016026518A2 (pt) | Ácidos hidroxâmicos heterocíclicos como inibidores da proteína desacetilase e inibidores duais de proteína desacetilase-proteína cinase e métodos de uso dos mesmos | |
BR112016015660A2 (pt) | formulação farmacêutica de neuregulina (nrg) e formulação farmacêutica liofilizada de neuregulina (nrg) | |
BR112018012981A2 (pt) | derivados do ácido meta-azacíclico amino benzoico como antagonistas de pan integrina com melhores propriedades farmacocinéticas | |
CL2020003277A1 (es) | Métodos de fabricación de composiciones de aminoácidos | |
BR112017003745A2 (pt) | inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico | |
BR112017023225A2 (pt) | inibidor de proteína cinase | |
DK3604304T3 (da) | Pyrrolo-pyridinderivatforbindelse, fremgangsmåde til fremstilling deraf og farmaceutisk sammensætning indeholdende denne som aktiv ingrediens til forebyggelse eller behandling af proteinkinase-relaterede sygdomme | |
EA202091400A1 (ru) | Производные пиррола в качестве ингибиторов асс | |
BR112019026577A8 (pt) | Compostos aminotiazol como inibidores de proteína quinase | |
BR112019007543A2 (pt) | inibidores de ácido alfa-amino-beta-carboximuconico semialdeido decarboxilase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/03/2017, OBSERVADAS AS CONDICOES LEGAIS |